9OF Stock Overview
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
BioRestorative Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.77 |
| 52 Week High | US$4.14 |
| 52 Week Low | US$0.76 |
| Beta | 61.13 |
| 11 Month Change | 82.47% |
| 3 Month Change | 45.08% |
| 1 Year Change | -57.04% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9OF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.0% | -1.8% | -0.1% |
| 1Y | -57.0% | -18.5% | 2.4% |
Return vs Industry: 9OF underperformed the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: 9OF underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| 9OF volatility | |
|---|---|
| 9OF Average Weekly Movement | 35.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 9OF's share price has been volatile over the past 3 months.
Volatility Over Time: 9OF's weekly volatility has increased from 26% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11 | Lance Alstodt | www.biorestorative.com |
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
BioRestorative Therapies, Inc. Fundamentals Summary
| 9OF fundamental statistics | |
|---|---|
| Market cap | €12.51m |
| Earnings (TTM) | -€5.10m |
| Revenue (TTM) | €139.51k |
89.7x
P/S Ratio-2.5x
P/E RatioIs 9OF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9OF income statement (TTM) | |
|---|---|
| Revenue | US$149.50k |
| Cost of Revenue | US$0 |
| Gross Profit | US$149.50k |
| Other Expenses | US$5.62m |
| Earnings | -US$5.47m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,657.78% |
| Debt/Equity Ratio | 0% |
How did 9OF perform over the long term?
See historical performance and comparison